ACADIA PHARMACEUTICALS INC. Earnings Per Share (Basic)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Earnings Per Share (Basic) of $0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2026-06-30 was $0.18, a 12.50% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2026-03-31 was $0.02, a 81.82% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2025-12-31 was $1.61, a 86.54% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.43, a 115.00% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for fiscal 2025 was $2.32, a 69.34% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for fiscal 2024 was $1.37.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for fiscal 2023 was -$0.37.
- ACADIA PHARMACEUTICALS INC. earnings per share, basic for fiscal 2022 was -$1.34.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.18 10-Q · filed 2026-08-05 | $0.21 10-Q · filed 2026-08-05 | $1.81 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.24 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | $0.02 10-Q · filed 2026-05-07 | $1.63 derived: net income ÷ weighted average shares · filed 2026-05-07 | $2.06 derived: net income ÷ weighted average shares · filed 2026-05-07 | $2.22 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | $1.61 derived: net income ÷ weighted average shares · filed 2026-02-26 | $2.04 derived: net income ÷ weighted average shares · filed 2026-02-26 | $2.20 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.32 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.43 10-Q · filed 2025-11-06 | $0.58 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.70 10-Q · filed 2025-11-06 | $1.56 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | $0.16 10-Q · filed 2026-08-05 | $0.27 10-Q · filed 2026-08-05 | $1.13 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.33 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | $0.11 10-Q · filed 2026-05-07 | $0.98 derived: net income ÷ weighted average shares · filed 2026-05-07 | $1.17 derived: net income ÷ weighted average shares · filed 2026-05-07 | $1.38 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | $0.86 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.06 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.26 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.37 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.20 10-Q · filed 2025-11-06 | $0.40 derived: net income ÷ weighted average shares · filed 2025-11-06 | $0.50 10-Q · filed 2025-11-06 | $0.78 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | $0.20 10-Q · filed 2025-08-07 | $0.30 10-Q · filed 2025-08-07 | $0.58 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.19 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | $0.10 10-Q · filed 2025-05-08 | $0.38 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | $0.28 10-K · filed 2024-02-28 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.37 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.40 10-Q · filed 2024-11-07 | -$0.39 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.65 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.01 10-Q · filed 2024-08-07 | -$0.26 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$0.27 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$0.26 10-K · filed 2024-02-28 | -$1.34 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$0.17 10-K · filed 2024-02-28 | -$1.08 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | -$0.21 10-K · filed 2024-02-28 | -$0.91 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$0.70 10-K · filed 2024-02-28 | |||
| 2021-12-31 | -$0.27 10-K · filed 2023-02-28 | -$1.05 10-K · filed 2024-02-28 | ||
| 2021-09-30 | -$0.09 10-K · filed 2023-02-28 | -$0.78 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$0.27 10-K · filed 2023-02-28 | -$0.69 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$0.42 10-K · filed 2023-02-28 | |||
| 2020-12-31 | -$1.79 10-K · filed 2023-02-28 | |||
| 2012-12-31 | -$0.38 10-K · filed 2013-03-12 | |||
| 2011-12-31 | -$0.44 10-K · filed 2013-03-12 | |||
| 2010-12-31 | $0.39 10-K · filed 2013-03-12 | |||
| 2009-12-31 | -$1.20 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |